Futures fall with bank earnings on deck 📉

Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Today is Tuesday, July 18th. I hope you have a great weekend. Let's get ready to trade! Markets 📈 The Nasdaq gained 0.9% on Monday in a strong weekly open for U.S. stocks. The Dow added 0.2%, and the S&P 500 gained 0.3%, while the small-cap Russell 2K outperformed with a 1.0% rally. Futures are treading water in early trading. S&P 500 contracts are currently showing a loss of less than 0.1%. Sponsored [Easy Money.... Hidden In Plain Sight]( Making a buck in today's uncertain market is no easy task. Fortunately, you can still generate steady returns from the market using this little secret... Trading Legend Chuck Hughes uses the same technique to generate steady payouts... And you can too. [See How Much You Can Earn Here]( Premarket Highlights 🔎 ⚪ None Not much to report in today's premarket. Futures are in a holding pattern ahead of today's busy trading session. What to Watch Today 👀 Retail Sales & Earnings Retail sales numbers drop today at 8:30 a.m., and it should give investors a status update on the health of the U.S. consumer. Given the U.S. economy's dependence on consumer spending, these figures are worth watching. Also, keep an eye on the earnings schedule because we have some big reports on the docket today. We'll also hear from Lockheed Martin, Prologis, and other big players. Most of the action will kick off before the open, so the results of these featured reports could have a big impact on today's trading session. Major Earnings 💰 Bank of America Corporation [BAC] ... AM Morgan Stanley [MS] ... AM Prologis, Inc. Reit [PLD] ... AM Lockheed Martin Corporation [LMT] ... AM Charles Schwab Corporation (The) [SCHW] ... AM PNC Financial Services Group, Inc. (The) [PNC] ... AM The Bank Of New York Mellon Corporation [BK] ... AM Interactive Brokers Group, Inc. [IBKR] ... PM Omnicom Group Inc. [OMC] ... PM J.B. Hunt Transport Services, Inc. [JBHT] ... PM Economy 🏗 - U.S. retail sales [Jun] ... 8:30a - Industrial production [Jun] ... 9:15a - Business inventories [May] ... 10:00a - Home builder confidence index [Jul] ... 10:00a Running Hot 🔥 Gainers - Rubicon Tech Class [RBT] >> +20.5% - Sentage Holdings [SNTG] >> +18.0% - Virax Biologics [VRAX] >> +9.7% - Predictive Oncology [POAI] >> +12.2% Decliners - Innovate Biopharma [NMTR] >> (59.8%) - Masimo Corp. [MASI] >> (29.1%) - CEL-SCI Corp [CVM] >> (17.8%) - Promis Neuroscience [PMN] >> (17.4%) Arch Capital Group [ACGL] - Last Close: $80.61 This mid-cap insurance stock is heating up. Shares of Arch Capital Group have been steadily marching higher for the past couple of weeks, and analysts are taking notice. Yesterday, Wells Fargo adjusted its price target on the stock to $90 from $83 and reiterated its "overweight" rating. The price target hike matched similar moves from RBC, UBS, and JMP Securities last week. ACGL jumped 4.6% on Monday as a result of the upgrades. It's currently leading the S&P 500 in the premarket with a 3.0% gain. My Take: ACGL has been gaining steady for the past couple of weeks. I am not sure what started the move, but it's certainly building up some momentum. This could be an interesting, albeit somewhat conservative, stock to watch. Biophytis [BPTS] - Last Close: $2.21 A crucial production deal is boosting shares of Biophytis. This morning, the micro-cap biotech announced it had landed a deal with SEQENS to produce the active compound for its Sarconeos drug candidate. Under the terms of the deal, SEQENS will produce the drug's active ingredient in France. Sarconeos was designed to treat severe COVID-19, sarcopenia, and Duchenne muscular dystrophy. Financial terms weren't disclosed, but BPTS is today's top stock, with a 60.1% gain on elevated trading volume in the premarket. My Take: Just last week, BPTS said it's seeking FDA approval for a Phase 3 study, now this. All things considered, It appears they're feeling very good about Sarconeos' chance at approval, but it's not over until the FDA gives the green light. Keep this one on your watchlist. Karyopharm Therapeutics [KPTI] - Last Close: $1.53 Karyopharm Therapeutics is getting a boost from a recent announcement. Late Monday, the biotech firm said the U.S. FDA had awarded a "Fast Track designation" to the development of selinexor for myelofibrosis patients. Just last month, Karyopharm kicked off a Phase 3 study of selinexor in combination with ruxolitinib in patients with myelofibrosis. The company says it expects to receive top-line data from the Phase 3 trial in 2025. HC Wainwright & CO reiterated its "buy" rating and $10 price target on KPTI in light of the news. KPTI is up 20.9% in today's premarket. My Take: KPTI has a way to go before those Phase 3 results come rolling in, so this could be a slow roll. However, share prices are showing some support around $1.50, so there could be a swing opportunity here. Aridis Pharmaceuticals [ARDS] - Last Close: $0.263 Aridis Pharma just published an upbeat clinical update. Late Monday, the pharma firm said the European Medicines Agency has agreed to its design for a Phase 3 trial of AR-301 pneumonia treatment. The agreement with the EMA covers "pneumonia caused by the Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients, according to the company." Aridis said its agreements with the EMA are similar to deal it made with the U.S. Food & Drug Administration. Shares of ARDS are up 34.4% on the news, and it's this morning's most active stock. My Take: ARDS is a tiny stock, but it's showing signs of life as of late, and this Phase 3 trial could deliver a valuable catalyst down the road. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. [Bots click here]( 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](